We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Xenon Pharmaceuticals announced Friday that a Phase II study of the experimental drug XEN801 for the treatment of moderate to severe facial acne failed to meet its primary endpoint. Shares in the company fell as much as 45 percent on the news.